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Concise Report
Validation of a Dutch translation of the fibromyalgia
impact questionnaire
T. R. Zijlstra1, E. Taal2, M. A. F. J. van de Laar1,2 and J. J. Rasker2
Objectives. To validate a Dutch translation of the fibromyalgia impact questionnaire (FIQ).
Materials and methods. Data were taken from two randomized clinical trials on Spa treatment and venlafaxine in fibromyalgia
(FM). Participants completed the Dutch FIQ and a set of validated questionnaires for general health (RAND-36), depression
(Beck depression inventory, BDI), pain (McGill pain questionnaire, MPQ) and fatigue (checklist individual strength, CIS).
Internal consistency within the FIQ item ‘physical functioning’ was studied using Cronbach’s . Test–retest reliability was
studied with intra-class-correlation (ICC) in a subsample of 76 control subjects over a 3 month period without specific
intervention. Construct validity was evaluated by correlating the FIQ to other questionnaires. Sensitivity to change was studied
using standardized response means (SRM).
Results. The study sample consisted of 213 women and 11 men (mean age 47 yrs, mean disease duration 11 yrs). Cronbach’s 
for the item ‘physical functioning’ was 0.91, indicating high internal consistency. Test–retest reliability was acceptable, with
ICC ranging from 0.45 for ‘morning tiredness’ to 0.71 for ‘physical function’. FIQ correlated significantly with the RAND-36,
with Spearman’s  ranging from 0.60 to 0.70 for items measuring the same concept. Similar patterns of correlation
were seen with MPQ, BDI and CIS. Sensitivity to change was sufficient, with SRM after Spa treatment ranging from 0.3 for
‘work days missed’ to 0.9 for ‘days felt good’. Similar SRM were found in the venlafaxine trial for patients reporting general
improvement.
Conclusion. The Dutch FIQ is a valid instrument for measuring health status in FM, showing sufficient reliability, construct
validity and responsiveness.
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The fibromyalgia impact questionnaire (FIQ) is a questionnaire to
assess the health status of women with fibromyalgia (FM)
syndrome [1]. It has been translated into several languages, and
has been recommended as a primary end-point in FM clinical
trials [2–10]. In order to join this international development,
we set out to make a Dutch version of the FIQ and evaluate
its psychometric properties.
Materials and methods
Patients
Data were used from two studies among patients aged 18–65 yrs
with primary FM, according to 1990 American College of
Rheumatology (ACR) criteria [11].
Study 1. This was a randomized controlled trial of Spa
treatment (n¼ 58) vs treatment as usual (n¼ 76). For details see
Zijlstra et al. [12].
Study 2. This was a 6 week, double blind, randomized trial of
venlafaxine (n¼ 45) vs placebo (n¼ 45). Subjects were recruited
from four out-patient rheumatology clinics, and through an
advertisement in the Dutch FM Patient Association Magazine.
Exclusion criteria were: severe depression needing drug treatment,
use of antidepressive drugs in the past 6 weeks, previous
use of venlafaxine, (chance of) pregnancy and medication or
comorbidity interfering with venlafaxine. This study has only been
published as an abstract [13].
Measures
FIQ. The FIQ consists of 10 items. The first item contains 10
questions on activities of daily living, each of which are scored in
a Likert format from 0 (always able to do) to 3 (never able to do).
The scores are added and divided by the number of valid scores to
yield one score for physical functioning. Item 2 is the number of
days (0–7) felt good during the past week. Item 3 asks for the
number of days off work during the past week (0–5). Items 4–10
(ability to do job, pain, fatigue, morning tiredness, stiffness,
anxiety and depression) are measured by 100mm visual analogue
scales. The scores of each item are standardized on a scale ranging
from 0–10 with higher scores indicating greater impairment.
The FIQ was translated from English into Dutch by one of the
investigators (T.R.Z.). Two adaptations were made. In item 3,
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the maximum number of work days missed was reduced to five,
in accordance with a normal working week in the Netherlands.
In the 4th item, ‘When you did go to work,’ was left out and the
word ‘job’ was translated with ‘werkzaamheden’ (meaning
‘activities’). In this way the question also applies to those without
a professional job, who make up a considerable part of the Dutch
FM population. We had our Dutch version back-translated by
a Dutch teacher of English. When comparing the original and the
back-translation, we found some differences, but these stem from
our cultural adaptations in items 3 and 4.
RAND-36. This is a validated Dutch translation of the Short
Form-36 (SF-36), a generic measure of self-reported health status,
also used in FM patients [14–18]. It covers eight domains of
functioning and well-being. Domain scores are standardised on a
0–100 scale with higher scores indicating better status.
Beck depression inventory (BDI). Depression was
measured with a Dutch version of the BDI [19, 20]. The score
ranges from 0 to 63.
McGill pain questionnaire (MPQ). The Dutch language
version of the MPQ comprises a set of 20 groups of three or four
words describing several characteristics of pain [21, 22]. Within
each group there is an increase in severity, reflected by an increase
in score. The scores are summed to yield a total pain rating index
(PRI-T, range 0–63).
Checklist individual strength (CIS). The CIS was used to
measure fatigue [23]. The questionnaire consists of 11 statements,
eight concerning subjective feelings of fatigue, and three concern-
ing activity. Each item is scored on a 7-point Likert scale from 1
(yes, correct) to 7 (no, incorrect). Thus, the scores range from 8–56
for subjective feelings and 3–21 for activity.
General improvement. In study 2, at 6 weeks, subjects were
asked if they had experienced general improvement during the
past weeks (yes/no).
Tender point assessment. A single observer (T.R.Z.) exam-
ined each patient by manual palpation of the 18 body sites defined
in the ACR criteria for FM [12]. The tender point score (TPS) was
the number of sites on which the patient stated that palpation was
painful (range 0–18). For the graded tender point score (GTPS)
each tender point was scored by the observer as 0 (no pain),
1 (mild pain, no grimace), 2 (spontaneous verbal reaction to
pain and grimace), 3 (severe pain with withdrawal) and the sum
of 18 points was recorded [24].
Procedures
Study 1. All subjects completed the questionnaires, and tender
point examinations were performed at baseline and at 3, 6 and
12 months during the follow-up period of the RCT. Subjects in
the intervention group were also assessed at 1 month, which was
1 week after the end of the Spa treatment.
Study 2. Assessments were performed at baseline and at
6 weeks.
Statistics
Internal consistency of the 10 questions in the first item of the
FIQ, physical functioning, was studied using Cronbach’s .
Test–retest reliability was studied with intra-class-correlation
(ICC) over a period of 3 months in a subsample of 76 control
subjects from study 1.
To study convergent validity of the FIQ, Spearman’s 
correlation coefficients were calculated with other questionnaires
and tests.
Responsiveness was assessed in two ways. Pre- and post-test
(1 month) results of the FIQ were compared in a subsample
of 58 subjects receiving Spa treatment in study 1. In study 2,
responsiveness was analysed from the patients’ perspective by
comparing pre- and post-test results of the FIQ in patients
who had experienced general improvement and in patients
who did not experience general improvement irrespective of
treatment with venlafaxine or placebo. Significance of changes
in FIQ scores from pre- to post-test was tested by Wilcoxon
signed rank tests. Standardized response means (SRM) were
calculated as the ratio of the mean change between baseline and
6 weeks to the standard deviation (S.D.) of that change.
The 95% confidence intervals (CI) for the SRM were
calculated under the assumption that change scores followed
a normal distribution and therefore the distribution of the
SRM could be approximated by a normal distribution, with a
mean of 0 and a S.D. of 1 divided by the square root of the sample
size [25].
Results
The study sample consisted of 213 women and 11 men. Mean age
was 47 yrs (range: 22–68, S.D.¼ 9.3) and mean disease duration
was 11 yrs (range: 0–42, S.D.¼ 8.2). The percentage of missing
values was below 3 for most items of the FIQ. The question ‘Were
you able to drive a car?’ was not applicable to 32 patients (14%)
without a driver’s license; and item 3 about ‘work days missed’
was only applicable to 91 patients (41%) because the other
patients were unemployed.
Internal consistency of the ‘physical functioning’ scale was
excellent (Cronbach’s ¼ 0.91).
The means and S.D. at baseline and test–retest results are
presented in Table 1. ICC coefficients of test–retest reliability
varied from 0.45 to 0.71.
In general, FIQ items correlated best with corresponding
items of the RAND-36 (Table 2). Thus, FIQ-physical function
correlated best with RAND-physical function, FIQ-pain with
RAND-pain, FIQ-fatigue and -morning tiredness with
RAND-vitality, and FIQ-anxiety and -depression with RAND-
role emotional and -mental health. Correlations between the FIQ
and other outcome measures showed the same pattern (supple-
mentary Table 3). FIQ-anxiety and -depression correlated best
with BDI (0.52 and 0.54), FIQ-pain with MPQ (0.44), and
FIQ-fatigue and -morning tiredness with CIS-subjective (0.61 and
0.53). All FIQ items correlated poorly with tender point scores
(all R< 0.23).
One week after Spa treatment the 58 subjects reported
statistically significant improvement (P 0.01) on all FIQ items,
with the exception of ‘work days missed’. However, this scale
was only applicable for 22 patients, and baseline scores were
already very good (mean¼ 0.8). SRMs ranged from 0.3 for
‘work days missed’ and for ‘depression’ to 0.9 for ‘days felt good’
(supplementary Table 4).
The FIQ scores also showed to be sensitive for changes
from the patient’s perspective (supplementary Table 5). Patients
who experienced general improvement after 6 weeks had
significantly improved scores (P 0.01) for most FIQ items,
while patients who did not experience general improvement
showed no improved FIQ scores. FIQ items ‘work days missed’
(only applicable for 11 patients, and a very good mean baseline
score of 0.4) and ‘anxiety’ showed not to be responsive for
perceived general improvement. SRMs for patients who perceived
to be improved for the other FIQ items ranged from 0.6
for ‘fatigue’ and ‘depression’ to 1.5 for ‘days felt good’.
SRMs for patients who perceived not to be improved ranged
from 0.4 to 0.2.
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Discussion
This study showed the Dutch FIQ to be a reliable, valid and
responsive measure.
In translating a questionnaire, cultural adaptations are
at least as important as the linguistic aspects. Our adaptation
in item 3 (a maximum of five working days per week) seems
logical and is in line with similar adaptations in the Swedish,
Hebrew and German versions [2, 3, 5]. After conversion to
a 0–10 score, results from countries with working weeks of
varying length can be compared directly. However, two other
problems remain. Firstly, this item does not take into account
if someone has a full-time or part-time job. Perhaps it would be
better to convert the score to a proportion of the individual’s
normal working week, instead of the full-time working week.
Secondly, item 3 only applies to subjects in paid employment.
Since the percentage of women in paid employment may
vary strongly between countries, it may prove difficult to
compare results from different countries. For this reason, we
also adapted item 4, using ‘activities’ instead of ‘job’. We prefer
not to restrict this item to paid employment, although the
impact of FM on unpaid activities such as housework may not
be exactly the same.
The internal consistency of item 1 proved excellent. Although
Offenbaecher and Sarz-Puttini reported even higher s (0.94),
others found values of 0.88 or less [1–9].
Test–retest reliability (ICC) over three months ranged from
0.45 (morning tiredness) to 0.71 (physical function). Although it is
usually recommended that the reliability should exceed 0.70 in
stable patients, we believe the reliability to be acceptable because
of the rather long time interval between measurements. All other
studies except the French and Korean found better test–retest
reliability [1–9]. This is probably due to a much shorter test–retest
interval of 7–10 days, as compared to 3 months in our study.
In other studies, test–retest reliability is measured with
Spearman’s or Pearson’s correlation coefficient. We have used
ICC instead because it is more appropriate. Correlation is a
measure of association, and repeated measurements may be
correlated but systematically different.
The significant correlations of most FIQ items with other
corresponding outcome measures suggest that the FIQ has
sufficient convergent validity. Only item 3 (work days missed)
did not correlate significantly, probably because of the small
number of subjects who had a job and the highly skewed
distribution of the data. In our study, FIQ-pain and other FIQ
items hardly correlated with TPSs. This is in line with findings
by Jacobs et al. [24], who found a weak correlation between TPSs
and self-reported pain. They concluded that TPSs and self-
reported pain represent different aspects of pain in FM. Four
validation studies also showed weak correlations between FIQ
items and TPSs [1, 4, 6, 7]. However, other studies showed much
stronger correlations [2, 5, 8, 9].
According to Cohen [26], an effect size (which is comparable
to SRM) of 0.2 indicates a small, 0.5 a moderate and 0.8 a large
effect. Thus, our version of the FIQ showed good sensitivity
to change after Spa treatment. More importantly, patients
who felt they had improved during the drug trial scored
better on most FIQ items, while patients who felt they had not
improved showed no improvement on the FIQ either. We can
conclude that the Dutch FIQ is a responsive measure. Sensitivity
TABLE 2. Non-parametric Spearman’s  correlations between FIQ and RAND-36 for 224 subjects with fibromyalgia
RAND-36 dimensions
Physical function Role physical Pain General health Social function Role emotional Mental health Vitality
Physical function 0.60*** 0.33*** 0.49*** 0.36*** 0.44*** 0.14* 0.10 0.33***
Days felt gooda 0.41*** 0.29*** 0.45*** 0.26*** 0.30*** 0.22*** 0.18** 0.44***
Work days missedb 0.27** 0.21* 0.35*** 0.08 0.16 0.13 0.09 0.26*
Job ability 0.47*** 0.44*** 0.64*** 0.31*** 0.41*** 0.27*** 0.23*** 0.40***
Pain 0.39*** 0.38*** 0.68*** 0.28*** 0.44*** 0.20** 0.17* 0.40***
Fatigue 0.39*** 0.37*** 0.46*** 0.31*** 0.50*** 0.26*** 0.24*** 0.64***
Morning tiredness 0.28*** 0.30*** 0.38*** 0.33*** 0.33*** 0.27*** 0.22*** 0.52***
Stiffness 0.30*** 0.36*** 0.51*** 0.30*** 0.32*** 0.20** 0.08 0.36***
Anxiety 0.24*** 0.16* 0.22*** 0.33*** 0.25*** 0.47*** 0.70*** 0.33***
Depression 0.15* 0.19** 0.16* 0.37*** 0.31*** 0.51*** 0.70*** 0.36***
*P 0.05; **P 0.01; ***P 0.001.
an¼ 222.
bn¼ 93.
TABLE 1. Mean scores and standard deviations (S.D.) at baseline and test-retest reliability of FIQ items
Study 1 (n¼ 134) Study 2 (n¼ 90) All patients (n¼ 224) Test-retest reliabilitya (n¼ 76)
FIQ-item Mean S.D. Mean S.D. Mean S.D. ICC 95% CI
Physical function 4.5 1.6 4.7 1.8 4.6 1.7 0.71 0.57–0.80
Days felt good 6.9 2.6 7.4 2.2 7.1 2.5 0.48 0.29–0.64
Work days missedb 0.8 2.4 2.8 3.9 1.6 3.2 0.68 0.41–0.84
Job ability 5.7 2.1 5.9 2.3 5.8 2.2 0.54 0.36–0.68
Pain 5.8 1.7 6.5 1.7 6.1 1.8 0.55 0.37–0.69
Fatigue 6.4 2.0 6.8 2.0 6.6 2.0 0.58 0.41–0.72
Morning tiredness 6.4 2.1 7.3 2.2 6.8 2.2 0.45 0.26–0.62
Stiffness 6.4 2.0 6.7 2.1 6.5 2.1 0.69 0.55–0.79
Anxiety 3.5 2.6 3.8 2.9 3.7 2.7 0.68 0.54–0.78
Depression 2.7 2.4 2.9 2.9 2.8 2.6 0.58 0.40–0.71
aTest–retest reliability after 3 months of treatment as usual in control subjects of study 1.
bWork days missed: study 1 (n¼ 57), study 2 (n¼ 36), total (n¼ 93), test–retest reliability (n¼ 27).
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to change has been examined for only a few other language
versions of the FIQ. The American and Spanish FIQ have
been shown to be responsive to perceived clinical improvement
[7, 10].
In conclusion, the Dutch FIQ is a reliable, valid and responsive
outcome measure.
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